Parth Narendran

Parth's research interest focusses on understanding the autoimmune destruction of insulin secreting beta cells that lead to type 1 diabetes and exploring how this process can be modulated. He is part of a national effort to explore the feasibility and acceptability of testing, monitoring and treating early-stage type 1 diabetes and is also exploring which therapies may be most effective in this space. He is the Chair of the MS Prevention Taskforce for the Multiple Sclerosis Society to explore treatment parallels across other conditions with similarities to type 1 diabetes. 

Parth leads the Diabetes Research Unit and the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital. He is the author of over 180 peer-reviewed publications including publications that have been cited by international bodies on Type 1 diabetes and its management. He currently serves on the Diabetes UK Scientific Research Advisory Group, and has previously served on the Diabetes UK Research Committee, the Research Advisory Board of the Diabetes Research and Wellness Foundation and Regional Advisory Committee for the NIHR RfPB programme, and was previous chair of the Academic subcommittee of The Association of British Clinical Diabetologists.

Parth reviews for all the major national and international diabetes journals. He contributes to the NIHR Horizon Scanning, and NICE Medical Technology reviews for new therapies.